Version 1.38.1 includes the following additions and updates, as noted in the Release Notes:
- Updates to the COVID-19 Vaccine Group to align ICE with the latest guidelines related to bivalent doses for patients 6 months and older.
- Minor updates to the DTP, Polio, Hep B and Orthopoxvirus vaccine groups.
- An updated ICE Implementation Guide with the following new CVX codes: (1) COVID-19 CVX codes: 230, 302, 518, 519, 520, 521; (2) DTP CVX codes: 195, 196; (3) Polio CVX codes: 195. A Google Sheet that lists all of the coded values in the Implementation Guide is also available.
Note that on 3/14/2023, the FDA amended the Emergency Use Authorization (EUA) for children ages 6 months and older who have previously completed a 3-dose monovalent Pfizer-BioNTech primary series. The recommendation states that those who fall into this category should receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the monovalent primary series. The ICE team is studying the new recommendation and will schedule a follow up release of ICE to add this recommendation. We will be in touch with information about the timing of the ICE release with these changes, via this e-mail list and posts to the ICE News Page.
If you have any questions, comments or suggestions, please e-mail us at ice@hln.com.